Literature DB >> 29525840

Reply to the letter to the editor: Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Rita Laiginhas1,2, Marta Inês Silva1, Manuel Sousa Falcão3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29525840     DOI： 10.1007/s00417-018-3952-6

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN： 0721-832X            Impact factor:   3.117


× No keyword cloud information.
  8 in total

1.  Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema.

Authors:  Peter A Campochiaro; David M Brown; Andrew Pearson; Sanford Chen; David Boyer; Jose Ruiz-Moreno; Bruce Garretson; Amod Gupta; Seenu M Hariprasad; Clare Bailey; Elias Reichel; Gisele Soubrane; Barry Kapik; Kathleen Billman; Frances E Kane; Kenneth Green
Journal:  Ophthalmology       Date:  2012-06-21       Impact factor: 12.079

2.  Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success.

Authors:  Rita Laiginhas; Marta Inês Silva; Vitor Rosas; Susana Penas; Vitor Adriano Fernandes; Amândio Rocha-Sousa; Ângela Carneiro; Fernando Falcão-Reis; Manuel Sousa Falcão
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-29       Impact factor: 3.117

3.  Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.

Authors:  Chirag P Shah; Jeffrey S Heier
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2016-09-01       Impact factor: 1.300

Review 4.  Therapeutic Options in Refractory Diabetic Macular Oedema.

Authors:  Sanket U Shah; Raj K Maturi
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

5.  Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.

Authors:  Bobak Bahrami; Thomas Hong; Meidong Zhu; Timothy E Schlub; Andrew Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-25       Impact factor: 3.117

6.  Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema.

Authors:  Ehsan Rahimy; Abtin Shahlaee; M Ali Khan; Gui-Shuang Ying; Joseph I Maguire; Allen C Ho; Carl D Regillo; Jason Hsu
Journal:  Am J Ophthalmol       Date:  2015-12-31       Impact factor: 5.258

7.  Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.

Authors:  Sonja G Karst; Jan Lammer; Christoph Mitsch; Manuela Schober; Janhvi Mehta; Christoph Scholda; Michael Kundi; Katharina Kriechbaum; Ursula Schmidt-Erfurth
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-10-28       Impact factor: 3.117

8.  Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.

Authors:  Antoine Herbaut; Franck Fajnkuchen; Lise Qu-Knafo; Sylvia Nghiem-Buffet; Bahram Bodaghi; Audrey Giocanti-Auregan
Journal:  J Ophthalmol       Date:  2017-08-16       Impact factor: 1.909
  8 in total
  1 in total

1.  Efficacy of switching therapy to aflibercept for patients with persistent diabetic macular edema: a systematic review and meta-analysis.

Authors:  Yilin Liu; Jiahan Cheng; Yunxia Gao; Ling Qin; Xiaoxue Min; Ming Zhang
Journal:  Ann Transl Med       Date:  2020-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.